India's pharma sector attracts more FDI in nine months than it did in FY22

6 March 2023

The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical industry in India has galloped in the third quarter of the current fiscal year, crossing the full financial year 2022 FDI in the first nine months. There was over $1 billion fund infusion in a single quarter.

From April to December 2022, foreign investors infused $1.82 billion into the sector, compared to $1.41 billion in 2021-22. In addition, the number of foreign funds that invested in the sector in the past three months is higher than the figure for the entire fiscal year 2020-21, which was $1.49 billion.

By September 2022, cumulative FDI in the pharma sector had crossed the $20 billion mark. Between October and December 2022, FDI infusion rose by 73% from $647 million in the same period last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK